argenx (NASDAQ:ARGX) Price Target Raised to $533.00 at HC Wainwright

argenx (NASDAQ:ARGX) had its target price upped by HC Wainwright from $504.00 to $533.00 in a research note issued to investors on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for argenx’s Q3 2025 earnings at $1.38 EPS, Q4 2025 earnings at $0.75 EPS and FY2027 earnings at $31.39 EPS.

A number of other equities analysts have also commented on the stock. Morgan Stanley cut their price objective on shares of argenx from $515.00 to $510.00 and set an overweight rating for the company in a research report on Tuesday, May 28th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a hold rating to a buy rating in a research report on Thursday, July 25th. Oppenheimer upgraded shares of argenx from a market perform rating to an outperform rating and set a $546.00 price objective for the company in a research report on Tuesday, July 23rd. William Blair restated a market perform rating on shares of argenx in a research report on Monday, June 17th. Finally, Piper Sandler raised their price objective on shares of argenx from $522.00 to $535.00 and gave the company an overweight rating in a research report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $540.37.

argenx Stock Up 0.9 %

ARGX opened at $499.05 on Friday. The company has a market capitalization of $29.84 billion, a price-to-earnings ratio of -88.17 and a beta of 0.64. The firm has a 50-day moving average price of $418.38 and a 200-day moving average price of $395.72. argenx has a twelve month low of $327.73 and a twelve month high of $532.59.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of ($0.89) by $1.34. The firm had revenue of $489.43 million during the quarter, compared to the consensus estimate of $436.66 million. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. During the same quarter last year, the company earned ($1.69) earnings per share. On average, sell-side analysts expect that argenx will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenx

Institutional investors have recently made changes to their positions in the business. Blue Trust Inc. raised its holdings in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after buying an additional 62 shares during the last quarter. J.Safra Asset Management Corp raised its holdings in argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after buying an additional 59 shares during the last quarter. GAMMA Investing LLC raised its holdings in argenx by 420.0% during the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after buying an additional 63 shares during the last quarter. Mather Group LLC. bought a new stake in argenx during the 1st quarter valued at $38,000. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in argenx during the 4th quarter valued at $60,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.